Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
I don’t say this often…that was a great article. Thanks for sharing.
😊 Right? It really stuck with me. One of those articles that ties together so many obvious and not so obvious pieces into a really clear picture. And in HuffPo no less!